Literature DB >> 27835737

A Radium-223 microgenerator from cyclotron-produced trace Actinium-227.

Diane S Abou1, Juile Pickett1, John E Mattson2, Daniel L J Thorek3.   

Abstract

The alpha particle emitter Radium-223 dichloride (223RaCl2) has recently been approved for treatment of late-stage bone metastatic prostate cancer. There is considerable interest in studying this new agent outside of the clinical setting, however the supply of 223Ra is limited and expensive. We have engineered a 223Ra microgenerator using traces of 227Ac previously generated from cyclotron-produced 225Ac. Radiochemically pure 223RaCl2 was made, characterized, evaluated in vivo, and the source was recovered in high yield for regeneration of the microgenerator. Copyright Â
© 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  (223)Ra; (227)Ac; (227)Th; Microgenerator; Purification

Year:  2016        PMID： 27835737      PMCID： PMC5136344          DOI： 10.1016/j.apradiso.2016.10.015

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  13 in total

1.  225Ac and 223Ra production via 800 MeV proton irradiation of natural thorium targets.

Authors:  J W Weidner; S G Mashnik; K D John; B Ballard; E R Birnbaum; L J Bitteker; A Couture; M E Fassbender; G S Goff; R Gritzo; F M Hemez; W Runde; J L Ullmann; L E Wolfsberg; F M Nortier
Journal:  Appl Radiat Isot       Date:  2012-07-10       Impact factor: 1.513

Review 2.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

3.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

Authors:  Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  Radiobiological effects and dose-LET spectra.

Authors:  R Wideröe
Journal:  Radiat Environ Biophys       Date:  1979-08-10       Impact factor: 1.925

5.  Production of actinium-225 for alpha particle mediated radioimmunotherapy.

Authors:  Rose A Boll; Dairin Malkemus; Saed Mirzadeh
Journal:  Appl Radiat Isot       Date:  2005-01-28       Impact factor: 1.513

6.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

7.  A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.

Authors:  Robert F Hobbs; Hong Song; Christopher J Watchman; Wesley E Bolch; Anne-Kirsti Aksnes; Thomas Ramdahl; Glenn D Flux; George Sgouros
Journal:  Phys Med Biol       Date:  2012-05-01       Impact factor: 3.609

8.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

9.  Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.

Authors:  Diane S Abou; David Ulmert; Michele Doucet; Robert F Hobbs; Ryan C Riddle; Daniel L J Thorek
Journal:  J Natl Cancer Inst       Date:  2015-12-18       Impact factor: 13.506

10.  Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.

Authors:  Penelope D Ottewell; Ning Wang; Joshua Meek; C Anne Fowles; Peter I Croucher; Colby L Eaton; Ingunn Holen
Journal:  Endocr Relat Cancer       Date:  2014-07-22       Impact factor: 5.678
View more
  13 in total

1.  The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates.

Authors:  Wen Jiang; David Ulmert; Brian W Simons; Diane S Abou; Daniel L J Thorek
Journal:  Nucl Med Biol       Date:  2018-05-08       Impact factor: 2.408

2.  Radiation Safety Considerations and Clinical Advantages of α-Emitting Therapy Radionuclides.

Authors:  Brian Serencsits; Bae P Chu; Neeta Pandit-Taskar; Michael R McDevitt; Lawrence T Dauer
Journal:  J Nucl Med Technol       Date:  2021-11-08

Review 3.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 4.  Targeted and Nontargeted α-Particle Therapies.

Authors:  Michael R McDevitt; George Sgouros; Stavroula Sofou
Journal:  Annu Rev Biomed Eng       Date:  2018-01-18       Impact factor: 9.590

5.  Preclinical Single Photon Emission Computed Tomography of Alpha Particle-Emitting Radium-223.

Authors:  Diane S Abou; Andrew Rittenbach; Ryan E Tomlinson; Paige A Finley; Benjamin Tsui; Brian W Simons; Abhinav K Jha; David Ulmert; Ryan C Riddle; Daniel L J Thorek
Journal:  Cancer Biother Radiopharm       Date:  2020-03-17       Impact factor: 3.099

6.  Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.

Authors:  Valery Radchenko; Alfred Morgenstern; Amir R Jalilian; Caterina F Ramogida; Cathy Cutler; Charlotte Duchemin; Cornelia Hoehr; Ferrid Haddad; Frank Bruchertseifer; Haavar Gausemel; Hua Yang; Joao Alberto Osso; Kohshin Washiyama; Kenneth Czerwinski; Kirsten Leufgen; Marek Pruszyński; Olga Valzdorf; Patrick Causey; Paul Schaffer; Randy Perron; Samsonov Maxim; D Scott Wilbur; Thierry Stora; Yawen Li
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 11.082

7.  Simultaneous Separation of Actinium and Radium Isotopes from a Proton Irradiated Thorium Matrix.

Authors:  Tara Mastren; Valery Radchenko; Allison Owens; Roy Copping; Rose Boll; Justin R Griswold; Saed Mirzadeh; Lance E Wyant; Mark Brugh; Jonathan W Engle; Francois M Nortier; Eva R Birnbaum; Kevin D John; Michael E Fassbender
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 8.  Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review.

Authors:  Bartosz Malinowski; Michał Wiciński; Nikola Musiała; Ilona Osowska; Mateusz Szostak
Journal:  Diagnostics (Basel)       Date:  2019-10-25

Review 9.  Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

10.  Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.

Authors:  Michael R McDevitt; Daniel L J Thorek; Takeshi Hashimoto; Tatsuo Gondo; Darren R Veach; Sai Kiran Sharma; Teja Muralidhar Kalidindi; Diane S Abou; Philip A Watson; Bradley J Beattie; Oskar Vilhemsson Timmermand; Sven-Erik Strand; Jason S Lewis; Peter T Scardino; Howard I Scher; Hans Lilja; Steven M Larson; David Ulmert
Journal:  Nat Commun       Date:  2018-04-24       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.